Last reviewed · How we verify

NCT05570370

Eardream Data Collection in Colombia Supported by ADDF

Status unknown Last updated 6 October 2022
What this trial tests

trial testing This is an observational study in Alzheimer Disease, Early Onset in 120 participants. Status unknown.

Timeline
1 August 2022
Primary endpoint
1 December 2023
1 December 2023

Quick facts

Lead sponsorSwiss Federal Institute of Technology
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment120
Start date1 August 2022
Primary completion1 December 2023
Estimated completion1 December 2023
Sites1 location across Colombia

Drugs / interventions tested

Conditions studied

Sponsor

Swiss Federal Institute of Technology

Who can join

Adults 20 to 75, any sex, with Alzheimer Disease, Early Onset. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Data collection based on this study will allow us to collect neurophysiological and cognitive data collected from in-ear EEG recordings of the Autosomal dominant alzheimer's disease population in Colombia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of This is an observational study

Trials testing the same drug.

Other recruiting trials for Alzheimer Disease, Early Onset

Currently open trials in the same condition.

Other Swiss Federal Institute of Technology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05570370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing